



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/542,175	07/14/2005	Peter Von Matt	TX/4-32732A	8299
1095 NOVARTIS CORPORATE INTELLECTUAL PROPERTY ONE HEALTH PLAZA 104/3 EAST HANOVER, NJ 07936-1080	7590 12/20/2006		EXAMINER KOSACK, JOSEPH R	
			ART UNIT 1626	PAPER NUMBER
SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE		
3 MONTHS	12/20/2006	PAPER		

**Please find below and/or attached an Office communication concerning this application or proceeding.**

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

<b>Office Action Summary</b>	Application No.	Applicant(s)
	10/542,175	VON MATT ET AL.
	Examiner Joseph Kosack	Art Unit 1626

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on 18 October 2006.
- 2a) This action is FINAL.                    2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 1-10 is/are pending in the application.
  - 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_ is/are allowed.
- 6) Claim(s) 1-10 is/are rejected.
- 7) Claim(s) \_\_\_\_\_ is/are objected to.
- 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.
 

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
  - a) All    b) Some \* c) None of:
    1. Certified copies of the priority documents have been received.
    2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
    3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)            | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)   | Paper No(s)/Mail Date: _____                                      |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>7/14/05 and 12/22/05</u> .                                    | 6) <input type="checkbox"/> Other: _____                          |

## DETAILED ACTION

Claims 1-10 are pending in the instant application.

### *Election/Restrictions*


Applicant's election with traverse of a single compound (Example 1) in the reply filed on October 18, 2006 is acknowledged. Applicant's arguments have been considered, but were not found to be persuasive.

The requirement is still deemed proper and is therefore made FINAL.

### *Status of the Claims*

Claims 1-10 are pending in the instant application. Claims 1-10 (in part) are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention. The withdrawn subject matter is patentably distinct from the elected subject matter as it differs in the structure and element and would require separate search considerations. In addition, a reference, which anticipates one group, would not render obvious the other.

Pursuant to Applicant's election of a single compound, the scope of the invention will be limited to the following substitutions of the base structure:



where:

- R is radical (a);
- R<sub>1</sub> is piperazine;
- all other substituents are as defined.

As a result of the election and the corresponding scope of the invention defined supra, the remaining subject matter of Claims 1-10 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to non-elected inventions.

***Priority***

The claim to priority as a 371 filing of PCT/EP04/01323 filed February 12, 2004 which claims priority to UK 03033198 filed February 13, 2003 has been granted in the instant application.

***Information Disclosure Statement***

The Information Disclosure Statements filed on July 14, 2005 and December 22, 2005 have been considered fully by the Examiner.

***Specification***

Applicant is reminded of the proper language and format for an abstract of the disclosure.

The abstract should be in narrative form and generally limited to a single paragraph on a separate sheet within the range of 50 to 150 words. It is important that the abstract not exceed 150 words in length since the space provided for the abstract on the computer tape used by the printer is limited. The form and legal phraseology often used in patent claims, such as "means" and "said," should be avoided. The abstract should describe the disclosure sufficiently to assist readers in deciding whether there is a need for consulting the full patent text for details.

The language should be clear and concise and should not repeat information given in the title. It should avoid using phrases which can be implied, such as, "The disclosure concerns," "The disclosure defined by this invention," "The disclosure describes," etc.

In chemical patent abstracts for compounds or compositions, the general nature of the compound or composition should be given as well as its use, e.g., "The compounds are of the class of alkyl benzene sulfonyl ureas, useful as oral anti-diabetics." Exemplification of a species could be illustrative of members of the class. For processes, the type reaction, reagents and process conditions should be stated, generally illustrated by a single example unless variations are necessary.

Complete revision of the content of the abstract is required on a separate sheet.

***Claim Objections***

Claims 1-10 are objected to for containing elected and non-elected subject matter. The elected subject matter have been identified supra.

***Claim Rejections - 35 USC § 112***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claim 10 rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

In In re Wands, 8 USPQ2d 1400 (1988), factors to be considered in determining whether a disclosure meets the enablement requirement of 35 U.S.C. § 112, first paragraph, have been described. They are:

1. the nature of the invention,
2. the state of the prior art,
3. the predictability or lack thereof in the art,
4. the amount of direction or guidance present,
5. the presence or absence of working examples,
6. the breadth of the claims,
7. the quantity of experimentation needed, and
8. the level of the skill in the art.

*The Nature of the Invention*

The nature of the invention is the prevention or treatment of all disorders associated with T lymphocytes and/or PKC or GSK-3 $\beta$  (claim 10).

*The State of the Prior Art and the Predictability or Lack Thereof in the Art*

The state of the prior art is that it involves screening *in vitro* and *in vivo* to determine which compounds exhibit the desired pharmacological activities (i.e. what compounds can treat which specific disease). There is no absolute predictability even in view of the seemingly high level of skill in the art. The existence of these obstacles establishes that the contemporary knowledge in the art would prevent one of ordinary skill in the art from accepting any therapeutic regimen on its face.

The instant claimed invention is highly unpredictable as discussed below: It is noted that the pharmaceutical art is unpredictable, requiring each embodiment to be individually assessed for physiological activity. *In re Fisher*, 427 F.2d 833, 166 USPQ 18 (CCPA 1970) indicates that the more unpredictable an area is, the more specific enablement is necessary in order to satisfy the statute. Also, while the specification lists several examples of diseases that are allegedly linked to with T lymphocytes and/or PKC or GSK-3 $\beta$ , no journal references have been provided to show the efficacy of the mechanism of treatment. Given the broad range of diseases in the specification, a clear delineation between the inhibition of with T lymphocytes and/or PKC or GSK-3 $\beta$  and which diseases can be treated by the mechanism should be provided and placed in the claims.

Hence, in the absence of a showing of correlation between all the diseases claimed as capable of treatment by mediating T lymphocytes and/or PKC or GSK-3 $\beta$ , one of skill in the art is unable to fully predict possible results from the administration of the compound of claim 1 due to the unpredictability of the role of mediating T lymphocytes and/or PKC or GSK-3 $\beta$ .

The Amount of Direction or Guidance Present and the Presence or Absence of Working

Examples

The specification teaches that the class of compounds claimed are reactive towards T lymphocytes and/or PKC or GSK-3 $\beta$ . The specification also provides examples of diseases mediated by these targets, and assay procedures to identify the ability of compounds to inhibit the targets. Limited data is provided for the class of compounds, as it seems that only examples 1, 10, 39, and 41 have been tested. It cannot be readily determined if the assays or examples provide support for treatment of diseases mediated by T lymphocytes and/or PKC or GSK-3 $\beta$ .

The Breadth of the Claims

The breadth of the claims is the treatment of all diseases mediated by T lymphocytes and/or PKC or GSK-3 $\beta$  with the compound of claim 1 (claim 10).

The Quantity of Experimentation Needed

The quantity of experimentation needed is undue experimentation. One of skill in the art would need to determine not only the binding affinity of the instant compounds to the T lymphocytes and/or PKC or GSK-3 $\beta$  receptor, but also the ability of antagonization of T lymphocytes and/or PKC or GSK-3 $\beta$  to treat the all associated diseases.

The Level of Skill in the Art

The level of skill in the art is high. However, due to the unpredictability in the pharmaceutical art, it is noted that each embodiment of the invention is required to be individually assessed for physiological activity by in vitro and in vivo screening to determine which compounds exhibit the desired pharmacological activity and which diseases would benefit from this activity.

Thus, the specification fails to provide sufficient support of the broad use of the compound of claim 1 for the treatment of diseases mediated T lymphocytes and/or PKC or GSK-3 $\beta$ . As a result, necessitating one of skill to perform an exhaustive search for which diseases can be treated by what compounds of claim 1 in order to practice the claimed invention.

Genentech Inc. v. Novo Nordisk A/S (CA FC) 42 USPQ2d 1001 , states that " a patent is not a hunting license. It is not a reward for search, but compensation for its successful conclusion" and "[p]atent protection is granted in return for an enabling disclosure of an invention, not for vague intimations of general ideas that may or may not be workable".

Therefore, in view of the Wands factors and In re Fisher (CCPA 1970) discussed above, to practice the claimed invention herein, a person of skill in the art would have to engage in undue experimentation to test which diseases can be treated by the compound encompassed in the instant claims, with no assurance of success.

This rejection can be overcome either deleting the claim or amending the claim and/or by providing evidence in the form of journal articles cited in an IDS or a declaration under 37 CFR 1.132 to show enablement.

Claim 10 rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

In the instant case, methods of treating diseases by mediating T lymphocytes and/or PKC or GSK-3 $\beta$  receptor with a compound of claim 1 are claimed.

In the art, it is recognized that in vitro results of binding to a receptor can be translated to possible success to treat diseases associated with the receptor in vivo provided that the function and activity of the receptor is known. For the reasons described above concerning the state of the art, the function and activity of the receptor at the time of the invention is still unknown. Although preliminary suggestions as to its functions are made, there is no knowledge in the art at the time of the invention to substantiate these suggestions to the treatment of any disease. Therefore, the claims do not meet the written description provision of 35 U.S.C. 112, first paragraph. This rejection can be overcome either deleting the claim or amending the claim and/or by providing evidence in the form of journal articles cited in an IDS or a declaration under 37 CFR 1.132 to show adequate written description.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:


1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1-10 rejected under 35 U.S.C. 103(a) as being unpatentable over Albert et al. (WO 02/38561 A1).


Art Unit: 1626

The instant invention is drawn to compounds of the formula




where: R is radical (a); R<sub>1</sub> is piperazine; and all other substituents are as defined. The instant invention is also drawn to its method of preparation and method of use.

Determination of the scope and content of the prior art (MPEP §2141.01)



Albert et al. teach compounds of the formula where: A is optionally substituted, Ra is H or optionally substituted C<sub>1-4</sub> alkyl, Rb is H or C<sub>1-4</sub> alkyl, R

 where G is CH, E is N, R<sub>11</sub> is a heterocyclic residue, and R<sub>12</sub> and R<sub>13</sub> are optional substitutions. See pages 1-2. Albert et al. teaches specifically piperazine in the R<sub>11</sub> substitution. One example is Example 163 on page 31. Albert et al. teaches the same process of forming the compounds. See page 6. Finally, Albert et al. teaches that the compounds are inhibitors of T lymphocytes and/or PKC. See pages 36-40.

Ascertainment of the difference between the prior art and the claims (MPEP §2141.02)

Albert et al. teaches a quinoline (benzofused pyridine) and not teach a pyridine ring in the R position.

Finding of prima facie obviousness--rational and motivation (MPEP §2142-2413)

Albert et al. teaches other monocycles versus the benzofused cycles with no loss of utility and no apparent loss of activity. Specifically, Albert et al. teaches the R position to be phenyl or napthelene, and pyrimidine or quinazoline. See page 1.

Therefore, it would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to follow the synthetic scheme of Albert et al. and pyridine for quinoline to make the claimed invention with a reasonable expectation of success. The motivation to do so is provided by Albert et al. Albert et al. teach the use of the synthesized compounds to treat various diseases mediated by T lymphocytes and/or PKC and the substitution for benzofused rings for the corresponding monocycles. See page 1 and 36-40.

Thus, the claimed invention as a whole was *prima facie* obviousness over the combined teachings of the prior art.

**Conclusion**


Claims 1-10 are rejected. Claims 1-10 are objected to.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Joseph Kosack whose telephone number is (571)-272-5575. The examiner can normally be reached on M-F 5:30 A.M. until 2:00 P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph M<sup>c</sup>Kane can be reached on (571)-272-0699. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

  
Joseph R. Kosack  
Joseph Kosack  
Patent Examiner  
Art Unit 1626

  
KAMAL A. SAEED, PH.D.  
PRIMARY EXAMINER  
Joseph K. M<sup>c</sup>Kane  
Supervisory Patent Examiner  
Art Unit 1626